% | $
Quotes you view appear here for quick access.


bec38 10 posts  |  Last Activity: Apr 24, 2015 2:17 PM Member since: Dec 29, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by phoqueyawholuvbjs Apr 23, 2015 2:41 PM
    bec38 bec38 Apr 24, 2015 2:17 PM Flag

    I thought you were Debbie Dootson now.

  • Reply to


    by bblf2015 Apr 23, 2015 6:24 PM
    bec38 bec38 Apr 23, 2015 8:04 PM Flag

    Where did you get this info. Post a link.

  • Dear Geron Stockholder,
    In 2014, we saw significant progress in the validation and clinical development of imetelstat as a potential transformative therapy
    in hematologic malignancies. First, updated preliminary data on myelofibrosis (MF) patients from the study being conducted by
    Dr. Ayalew Tefferi at Mayo Clinic (MF Pilot Study) indicated that six out of seven patients maintained their complete or partial
    remissions as of the September 10, 2014 data cut. Second, data from translational studies conducted in independent laboratories
    supported the clinical results reported by Dr. Tefferi, offering insight into the potential mechanisms of action for imetelstat and thus
    providing support for broader development of the drug within hematologic malignancies. Third, we received acknowledgement
    from the FDA that imetelstat could be developed for high risk myeloid malignancies, such as MF. Fourth, we entered into a worldwide
    collaboration and license agreement with one of the top oncology franchises in the world, Janssen Biotech, Inc., for the global
    development and commercialization of imetelstat for all indications. All of these achievements in 2014 positions imetelstat to
    become closer to a reality for patients.
    We believe our collaboration with Janssen has the potential to become highly beneficial for our stockholders and the patients
    we serve – it allows imetelstat to be developed for the greatest number of indications as expeditiously as possible, and with
    potential higher probability of success. Under the collaboration, Janssen is responsible for the development, manufacturing and
    commercialization of, and seeking regulatory approval for, imetelstat worldwide. The collaboration agreement became effective on
    December 15, 2014 and we received $35 million from Janssen as an upfront payment. We are also eligible to receive payments up to
    a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on

  • San Francisco (April 10, 2015, 7:02 PM ET) -- A California federal judge
    on Friday trimmed a consolidated proposed shareholder class action accusing
    Geron Corp. of improperly touting the prospects of its cancer drug imetelstat
    before the U.S. Food and Drug Administration put a hold on the drug's clinical
    trial over concerns of liver toxicity.

    In a brief hearing, U.S. District Court Judge Charles R. Breyer partially
    granted Geron's motion to dismiss the case based on some of the drugmaker's
    statements that the plaintiffs claimed were misleading — and tossed many of them
    with prejudice. However, he said that the plaintiffs may continue to press their
    claims based on other statements Geron made to the press, investors and the U.S.
    Securities and Exchange Commission, particularly between December of 2012 and
    August of 2013.

    Judge Breyer didn't take argument on the motion during Friday's hearing, and
    refused to issue a lengthy order explaining his decision. “I'm not going to
    write 30 pages,” he told attorneys. “I might write a couple of conclusory
    sentences if it's helpful.”

    Judge Breyer dismissed the plaintiffs' claims on a number of statements that
    Geron made during an April 2013 conference call to discuss its financial
    results, along with a slew of statements it made in November and December of
    2013 regarding preliminary data from its imetelstat trial as well as its
    financial results from the third quarter of 2013. The plaintiffs allege that in
    those and other statements, including those that Judge Breyer refused to
    dismiss, Geron didn't adequately disclose the elevation of certain liver enzymes
    in patients who took the drug, court records show.

    Geron argued in its motion that the plaintiffs' “puzzle-style pleading” didn't
    adequately identify any false or misleading statements. The drugmaker said that
    it “repeatedly, timely and accurately disclosed the results” from the ongoing
    imetelstat trials, arguing that the plaintiffs' allegat

  • bec38 bec38 Apr 3, 2015 2:16 PM Flag

    ‘Not a smidgen’

  • Reply to

    Hillary's Greatest Accomplishments

    by fraud_z_buster Mar 30, 2015 12:29 PM
    bec38 bec38 Mar 30, 2015 1:49 PM Flag


  • from The Street or anyone else.

  • Reply to

    OT: Bill O'Reilly lied about war zone reporting

    by notthatflop Feb 20, 2015 2:16 PM
    bec38 bec38 Feb 23, 2015 8:41 PM Flag

    O'Reilly is vindicated, MotherJones been Cornholed by Corn.

6.97+0.17(+2.50%)Nov 13 3:59 PMEST